Starsource Multi

Why is Starsource Multitrade Ltd falling/rising?

As of 18-Jul, Starsource Multitrade Ltd's stock price is rising to 81.00, reflecting a 0.91% increase after a trend reversal. Despite this short-term gain, the stock has experienced significant long-term declines and is trading below all major moving averages, indicating a bearish trend and cautious investor sentiment.

As of 18-Jul, Starsource Multitrade Ltd's stock price is rising, currently at 81.00, reflecting a change of 0.73 (0.91%) upward. This increase comes after a trend reversal, as the stock has gained after four consecutive days of decline. Additionally, it has outperformed its sector by 1.55% today. However, despite this positive movement, the stock has shown significant declines over longer periods, with a year-to-date drop of 29.38% and a one-year decline of 33.58%. <BR><BR>The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally bearish trend. Furthermore, there has been a notable decrease in investor participation, with delivery volume on 16 July falling by 86.11% compared to the 5-day average. This suggests that while the stock is experiencing a brief rise, the overall sentiment remains cautious due to the significant declines in the past and reduced trading activity.

Which are the latest news on Starsource Multi?

What does Starsource Multi do?

Starsource Multitrade Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, established in 1942, with recent quarterly results showing no net profit and a market cap of INR 17 Cr. Key financial metrics include a negative return on equity of -947.29% and a debt-equity ratio of -0.01.

Overview:<BR>Starsource Multitrade Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was established in August 1942. It has undergone status changes, including the disposal of its previous business due to increased competition and the flow of new drugs. The latest quarterly results reported are for March 2026, showing no net profit.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 17 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 32<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.01<BR>Return on Equity: -947.29%<BR>Price-to-Book: 13.25<BR><BR>Contact Details:<BR>Address: 5 Kumud Apartment CHS Ltd, Karnik Road Chikan Ghar Kalyan Thane Maharashtra : 421301<BR>Tel: 91-022-22078381/22078382<BR>Email: chemopharmalab@gmail.com<BR>Website: http://www.thechemopharmalaboratoriesltd.com

How big is Starsource Multi?

As of 10th June, Starsource Multitrade Ltd has a market capitalization of 17.00 Cr and reported Net Sales of 0.53 Cr with a Net Profit loss of 11.87 Cr over the latest four quarters.

As of 10th June, Starsource Multitrade Ltd has a market capitalization of 17.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.53 Cr. However, it experienced a loss of 11.87 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2016, with Shareholder's Funds amounting to 3.67 Cr and Total Assets valued at 3.87 Cr.

Who are in the management team of Starsource Multi?

The management team of Starsource Multi includes Ashok Somani (Executive Director & CFO), Toby Antony, Shanta Somani, Mathura Prasad Sharma, Bhavin Sheth (CEO), Nandkumar Pareek, and Unnatti Jain (Company Secretary & Compliance Officer). They oversee the company's operations and governance.

The management team of Starsource Multi includes the following individuals:<BR><BR>1. **Ashok Somani** - Executive Director & CFO<BR>2. **Toby Antony** - Independent Director<BR>3. **Shanta Somani** - Non-Executive Director<BR>4. **Mathura Prasad Sharma** - Independent Director<BR>5. **Bhavin Sheth** - Director & Chief Executive Officer<BR>6. **Nandkumar Pareek** - Independent Director<BR>7. **Unnatti Jain** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and governance.

Who are the peers of the Starsource Multi?

Peers of Starsource Multi include Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Cian Healthcare, Zenith Health, Ortin Global, Colinz Labs, Mono Pharmacare, and Saroja Pharma In. Parmax Pharma has the highest 1-year return at 48.68%, while Dipna Pharmachem has the lowest at -66.76%.

Peers: The peers of Starsource Multi are Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Cian Healthcare, Zenith Health, Ortin Global, Colinz Labs, Mono Pharmacare, and Saroja Pharma In.<BR><BR>Quality Snapshot: Below Average management risk is observed at Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Cian Healthcare, Zenith Health, Ortin Global, Colinz Labs, and Mono Pharmacare, while Average management risk is found at Saroja Pharma In. Growth is Excellent at Dipna Pharmachem, while Below Average growth is noted at Parmax Pharma, Desh Rakshak, Cian Healthcare, and the rest. Capital Structure ratings show Good at Zenith Health and Colinz Labs, while Below Average is seen at Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Cian Healthcare, Ortin Global, Mono Pharmacare, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Parmax Pharma at 48.68%, while Dipna Pharmachem has the lowest at -66.76%, with Starsource Multi's own 1-year return at -0.89% being better than Dipna Pharmachem's. Additionally, the six-month return is negative for Dipna Pharmachem, Zenith Health, and Mono Pharmacare.

When is the next results date for Starsource Multitrade Ltd?

The next results date for Starsource Multitrade Ltd is 29 May 2026.

The next results date for Starsource Multitrade Ltd is scheduled for 29 May 2026.

How has been the historical performance of Starsource Multi?

The historical performance of Starsource Multi for the year ending March 2016 was poor, with total operating income of 0.49 Cr, a loss before tax of -1.35 Cr, and a negative EPS of -9.66, indicating significant financial challenges. The company had total liabilities of 3.87 Cr against shareholder's funds of 3.67 Cr, reflecting a precarious financial position.

Answer:<BR>The historical performance of Starsource Multi for the year ending March 2016 shows a challenging financial situation with negative profitability and limited operational activity.<BR><BR>Breakdown:<BR>In March 2016, Starsource Multi reported total operating income of 0.49 Cr, derived primarily from other operating income, as net sales were recorded at 0.00 Cr. The total expenditure, excluding depreciation, amounted to 1.84 Cr, leading to an operating profit (PBDIT) of -1.35 Cr. Consequently, the profit before tax also stood at -1.35 Cr, resulting in a profit after tax of -1.45 Cr. The company had a negative earnings per share (EPS) of -9.66 and an operating profit margin of -273.78%. On the balance sheet, shareholder's funds totaled 3.67 Cr, with total liabilities at 3.87 Cr, indicating a precarious financial position. The cash flow from operating activities was -2.09 Cr, while cash flow from investing activities showed a positive inflow of 2.15 Cr, leading to a net cash inflow of 0.06 Cr by the end of the period, with closing cash and cash equivalents at 0.44 Cr.

Who are the top shareholders of the Chemo Pharma Lab?

The top shareholders of Chemo Pharma Lab are Citric India Ltd with 24.63% and Shree Consultation And Services Pvt Ltd with 3.63%. Individual investors own a combined 65.29%, with no mutual funds or foreign institutional investors currently holding shares.

The top shareholders of Chemo Pharma Lab include Citric India Ltd, which holds the highest promoter stake at 24.63%. Additionally, Shree Consultation And Services Pvt Ltd is the highest public shareholder with a holding of 3.63%. Individual investors collectively own 65.29% of the company. There are no mutual funds or foreign institutional investors currently holding shares in Chemo Pharma Lab.

Is Chemo Pharma Lab overvalued or undervalued?

As of April 25, 2023, Chemo Pharma Lab is considered a risky investment due to its overvaluation indicated by a PE ratio of 19.25, negative EV to EBIT and EBITDA, and a low ROCE of -3.04%, especially when compared to its peers, and it has recently underperformed the market with a one-week return of -9.53%.

As of 25 April 2023, Chemo Pharma Lab's valuation grade has moved from does not qualify to risky, indicating a shift in its perceived investment quality. The company appears to be overvalued based on its current metrics, particularly with a PE ratio of 19.25 and a negative EV to EBIT and EV to EBITDA of -12.50. Additionally, the ROCE stands at -3.04%, which raises concerns about its operational efficiency.<BR><BR>In comparison to its peers, Chemo Pharma Lab's valuation is notably less attractive. For instance, Altius Telecom, categorized as very attractive, has a PE ratio of 52.97, while other peers like Embassy Off.REIT and Inventurus Knowl are deemed very expensive with PE ratios of 23.06 and 56.63, respectively. Chemo Pharma Lab's stock has underperformed recently, with a one-week return of -9.53% compared to a 1.41% gain in the Sensex, further supporting the notion that it is currently overvalued.

What is the technical trend for Chemo Pharma Lab?

As of March 17, 2025, Chemo Pharma Lab's technical trend is bullish, supported by strong upward momentum from the MACD and KST, despite mixed signals from other indicators.

As of 17 March 2025, the technical trend for Chemo Pharma Lab has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting a strong upward momentum. The KST also confirms this bullish stance on both time frames. While the RSI shows no signal, the Bollinger Bands indicate a mildly bullish trend on both weekly and monthly charts. The daily moving averages are mildly bullish, suggesting some short-term strength. Overall, the current technical stance is bullish with a strong momentum indicated by the MACD and KST, despite some mixed signals from other indicators.

Has Chemo Pharma Lab declared dividend?

No Dividend History Available